SpyGlass To Boost Ophthalmic Drug Adherence With Intraocular Delivery Platform

After $90m Series C

Emerging Company Profile: The US biotech SpyGlass is gearing up for a Phase I/II trial in glaucoma after recently closing a $90m fundraising to help advance its intraocular delivery platform to address poor treatment adherence in chronic eye diseases.  

Emerging Company Profile: SpyGlass Pharma
SpyGlass' Drug-Eluting Pads Are Attached To The Haptics Of The Lens • Source: Shutterstock
Key Takeaways:
  • The $90m raise was led by RA Capital Management and included both old and new investors.

  • SpyGlass designs intraocular lenses secured by drug-eluting pads to deliver controlled drug release.

  • Work is underway for an IND filing in glaucoma with a Phase I/II trial planned for later this year.

SpyGlass Pharma is using its proprietary intraocular drug-delivery system to develop more convenient treatment options for chronic eye diseases with the help of a

The round was led by RA Capital Management alongside historical investors New Enterprise Associates and Vensana Capital, and also included new investors Samsara BioCapital and Vertex Ventures

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Emerging Company Profiles

More from Start-Ups & SMEs